8-K: Galera Therapeutics Merges, Becomes Obsidian Subsidiary

Sentiment:

Current Report (Form 8-K) 3 August 2026 9:54 PM

📋All filings for Galera Therapeutics, INC

Galera Therapeutics, Inc. has completed its merger with Obsidian Therapeutics, Inc., becoming a wholly owned subsidiary and ceasing its OTCQB listing.

Capital raiseThe filing mentions a 'Concurrent PIPE Financing' which resulted in the issuance of 29,165,559 shares of Parent Common Stock to investors.

Summary

Galera Therapeutics, Inc. has completed a merger with Obsidian Therapeutics, Inc. (formerly Gazelle Parent, Inc.) on August 3, 2026.
The company is now a wholly owned subsidiary of Obsidian Therapeutics, Inc.
Galera's common stock will cease to be quoted on the OTCQB Market.
Shareholders of record as of July 31, 2026, will receive contingent value rights (CVRs) for potential future proceeds from specific product developments or divestitures.
The merger is structured as a tax-free reorganization under Section 368(a) of the Internal Revenue Code.
Approximately 61.7 million shares of Obsidian Therapeutics, Inc. common stock were issued and outstanding immediately following the merger.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to the company's effective dissolution and the contingent nature of any future value for shareholders.

Positives

The merger is intended to qualify as a tax-free reorganization, potentially benefiting securityholders.
Contingent Value Rights (CVRs) offer shareholders a potential to receive future proceeds from specific product developments or divestitures.

Negatives

Galera Therapeutics, Inc. ceases to exist as an independent entity.
The company's common stock will be delisted from the OTCQB Market.
The value of CVRs is contingent and not guaranteed, with no assurance of payment.
Shareholders of Galera now hold a very small percentage (approximately 1.2%) of the combined company's common stock on a fully diluted basis.

Risks

There is no assurance that any holders of CVRs will receive payments.
The contingent payments under the CVR Agreement are contractual rights only and are not transferable except in limited circumstances.
The CVRs do not represent any equity or ownership interest in the parent company or its affiliates.
No interest will accrue on any amounts payable in respect of the CVRs.

Future Outlook

The future outlook for former Galera shareholders is tied to the success of the development and commercialization of the 'Legacy Product' and the 'Supportive-Care Product Divestiture' by Obsidian Therapeutics, Inc., with potential payments contingent on net proceeds received within specified timeframes.

Management Comments

J. Mel Sorensen, M.D. signed the report as President and Chief Executive Officer of Galera Therapeutics, Inc.

Industry Context

StockSavvy.ai notes that this merger represents a consolidation trend within the biotechnology sector, where smaller companies often merge or are acquired by larger entities to leverage resources and advance drug development pipelines.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Director	J. Mel. Sorensen		August 3, 2026	Resignation in accordance with the Merger Agreement.
Director	Michael Friedman		August 3, 2026	Resignation in accordance with the Merger Agreement.
Director	Nancy Chang		August 3, 2026	Resignation in accordance with the Merger Agreement.
Director	Lawrence Alleva		August 3, 2026	Resignation in accordance with the Merger Agreement.
Director	Kevin Lokay		August 3, 2026	Resignation in accordance with the Merger Agreement.
Officer of the Company (surviving corporation)		Madan Jagasia	August 3, 2026	Appointment effective upon closing of the Mergers.
Officer of the Company (surviving corporation)		Julie Feder	August 3, 2026	Appointment effective upon closing of the Mergers.
Officer of the Company (surviving corporation)		Parameswaran Hari	August 3, 2026	Appointment effective upon closing of the Mergers.
Officer of the Company (surviving corporation)		Dana Alexander	August 3, 2026	Appointment effective upon closing of the Mergers.
President and Principal Executive Officer	J. Mel Sorensen		August 3, 2026	Resignation immediately after closing of the Mergers.
Treasurer and Principal Financial and Accounting Officer	Joel Sussman		August 3, 2026	Resignation immediately after closing of the Mergers.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Amendments to Certificate of Incorporation and Bylaws	The Company's certificate of incorporation was amended and restated, and its bylaws were amended and restated to be identical to those of Galera Merger Sub prior to the merger.	August 3, 2026	Reflects the change in corporate structure and ownership following the merger.

Stakeholder Impact

Shareholders: Receive CVRs for potential future value, but their equity stake in the combined entity is significantly diluted (1.2% on a fully diluted basis).
Creditors: The merger and subsequent delisting may impact the perception of the company's financial stability and future obligations.
Employees: Potential changes in roles and responsibilities within the new corporate structure of Obsidian Therapeutics, Inc.

Next Steps

Galera Therapeutics, Inc. will cease to be quoted on the OTCQB Market.
The company will file a Certification and Notice of Termination of Registration on Form 15 to terminate its registration and suspend reporting obligations under the Exchange Act.
Holders of CVRs will await potential future proceeds from the development, commercialization, licensing, sale, or disposition of the Legacy Product and the Supportive-Care Product Divestiture.

Key Dates

Date	Description
July 31, 2026	Record date for determining stockholders eligible to receive CVRs.
August 3, 2026	Closing Date of the Mergers; effective date of the merger and name change of parent company.
August 3, 2026	Company intends to file Form 15 to terminate registration and suspend reporting obligations.
90 days after August 3, 2026	Termination of registration of Galera Common Stock will become effective, unless earlier terminated by the SEC.

Recommendation

sell

The company has effectively been acquired and dissolved, with its shareholders receiving a minimal equity stake in the acquiring entity and only contingent rights to future value. The delisting further diminishes liquidity and direct investment potential for former Galera shareholders.

Keywords

Merger, Acquisition, Subsidiary, Contingent Value Rights, Delisting, Tax-Free Reorganization, Biotechnology, Pharmaceuticals

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.